{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urological+Disease&page=59", "query": { "condition": "Urological Disease", "page": 59 }, "page_size": 10 }, "pagination": { "page": 59, "page_size": 10, "total_count": 7068, "total_pages": 707, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urological+Disease&page=60&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urological+Disease&page=58&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T21:13:33.311Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06318676", "title": "A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Impairment" ], "interventions": [ { "name": "Mezigdomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "82 Years", "sex": "ALL", "summary": "18 Years to 82 Years" }, "enrollment_count": 26, "start_date": "2024-03-21", "completion_date": "2024-11-15", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-10-29T21:13:33.311Z", "location_count": 3, "location_summary": "Miami Lakes, Florida • Orlando, Florida", "locations": [ { "city": "Miami Lakes", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06318676" }, { "nct_id": "NCT03339076", "title": "A Prospective Evaluation of the Catheter Science M3 \"Mini Catheter\" for Patients With Prostatic", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Urinary Retention" ], "interventions": [ { "name": "M3 \"MINI CATHETER\"", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Dr. Gaines W. Hammond Jr. MD FACS", "sponsor_class": "INDIV", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "MALE", "summary": "50 Years and older · Male only" }, "enrollment_count": 50, "start_date": "2017-07-07", "completion_date": "2018-03", "has_results": false, "last_update_posted_date": "2017-11-21", "last_synced_at": "2026-10-29T21:13:33.311Z", "location_count": 1, "location_summary": "Lakeland, Florida", "locations": [ { "city": "Lakeland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03339076" }, { "nct_id": "NCT07327489", "title": "Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Immunotherapy", "Advanced Solid Tumors Cancer", "Bladder Cancer", "TNBC, Triple Negative Breast Cancer", "Colorectal Cancer", "DMMR Colorectal Cancer", "MSI-H Colorectal Cancer", "Endometrial Cancer", "Head and Neck Cancer", "Kidney Cancer", "Liver Cancer", "NSCLC (Non-small-cell Lung Cancer)", "Skin Cancer", "Melanoma (Skin Cancer)" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Elephas", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2000, "start_date": "2025-04-14", "completion_date": "2038-04", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-29T21:13:33.311Z", "location_count": 8, "location_summary": "Fort Smith, Arkansas • Frederick, Maryland • Springfield, Missouri + 4 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Frederick", "state": "Maryland" }, { "city": "Springfield", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07327489" }, { "nct_id": "NCT03633110", "title": "Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cutaneous Melanoma", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Urothelial Carcinoma", "Renal Cell Carcinoma" ], "interventions": [ { "name": "GEN-009 Adjuvanted Vaccine", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genocea Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2018-08-29", "completion_date": "2022-02-28", "has_results": false, "last_update_posted_date": "2022-04-19", "last_synced_at": "2026-10-29T21:13:33.311Z", "location_count": 11, "location_summary": "La Jolla, California • Santa Monica, California • Aurora, Colorado + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03633110" }, { "nct_id": "NCT01928082", "title": "The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypercalciuria", "Hypercalciuria, Familial Idiopathic", "Osteopenia", "Osteoporosis" ], "interventions": [ { "name": "Transdermal estradiol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "69 Years", "sex": "FEMALE", "summary": "40 Years to 69 Years · Female only" }, "enrollment_count": 1, "start_date": "2013-08-01", "completion_date": "2014-08-01", "has_results": true, "last_update_posted_date": "2018-12-10", "last_synced_at": "2026-10-29T21:13:33.311Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01928082" }, { "nct_id": "NCT04246996", "title": "Gentamicin Intravesical Efficacy for Infection of Urinary Tract", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Postoperative Urinary Tract Infection", "Pelvic Organ Prolapse", "Stress Urinary Incontinence" ], "interventions": [ { "name": "gentamicin sulfate", "type": "DRUG" }, { "name": "Catheter clamping only", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kaiser Permanente", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 370, "start_date": "2020-01-29", "completion_date": "2021-12-05", "has_results": true, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-10-29T21:13:33.311Z", "location_count": 2, "location_summary": "La Jolla, California • San Diego, California", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04246996" }, { "nct_id": "NCT06099782", "title": "A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Renal Cell Carcinoma", "Melanoma" ], "interventions": [ { "name": "Pembrolizumab (+) Berahyaluronidase alfa", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 147, "start_date": "2023-12-26", "completion_date": "2027-02-15", "has_results": true, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-10-29T21:13:33.311Z", "location_count": 8, "location_summary": "Alexander City, Alabama • Anchorage, Alaska • Springdale, Arkansas + 5 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Greenbrae", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06099782" }, { "nct_id": "NCT03655223", "title": "Early Check: Expanded Screening in Newborns", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Spinal Muscular Atrophy", "Fragile X Syndrome", "Fragile X - Premutation", "Duchenne Muscular Dystrophy", "Hyperinsulinemic Hypoglycemia, Familial 1", "Diabetes Mellitus", "Adrenoleukodystrophy, Neonatal", "Medium-chain Acyl-CoA Dehydrogenase Deficiency", "Very Long Chain Acyl Coa Dehydrogenase Deficiency", "Beta-ketothiolase Deficiency", "Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency", "Primary Hyperoxaluria Type 1", "Congenital Bile Acid Synthesis Defect Type 2", "Pyridoxine-Dependent Epilepsy", "Hereditary Fructose Intolerance", "Hypophosphatasia", "Hyperargininemia", "Mucopolysaccharidosis Type 6", "Argininosuccinic Aciduria", "Citrullinemia, Type I", "Wilson Disease", "Maple Syrup Urine Disease, Type 1A", "Maple Syrup Urine Disease, Type 1B", "Biotinidase Deficiency", "Neonatal Severe Primary Hyperparathyroidism", "Intrinsic Factor Deficiency", "Usher Syndrome Type 1D/F Digenic (Diagnosis)", "Cystic Fibrosis", "Stickler Syndrome Type 2", "Stickler Syndrome Type 1", "Alport Syndrome, Autosomal Recessive", "Alport Syndrome, X-Linked", "Carbamoyl Phosphate Synthetase I Deficiency Disease", "Carnitine Palmitoyl Transferase 1A Deficiency", "Carnitine Palmitoyltransferase II Deficiency", "Cystinosis", "Chronic Granulomatous Disease", "Cerebrotendinous Xanthomatoses", "Maple Syrup Urine Disease, Type 2", "Severe Combined Immunodeficiency Due to DCLRE1C Deficiency", "Thyroid Dyshormonogenesis 6", "Thyroid Dyshormonogenesis 5", "Supravalvar Aortic Stenosis", "Factor X Deficiency", "Hemophilia A", "Hemophilia B", "Tyrosinemia, Type I", "Fructose 1,6 Bisphosphatase Deficiency", "Glycogen Storage Disease Type I", "G6PD Deficiency", "Glycogen Storage Disease II", "Galactokinase Deficiency", "Mucopolysaccharidosis Type IV A", "Galactosemias", "Guanidinoacetate Methyltransferase Deficiency", "Agat Deficiency", "Glutaryl-CoA Dehydrogenase Deficiency", "Gtp Cyclohydrolase I Deficiency", "Hyperinsulinism-Hyperammonemia Syndrome", "Primary Hyperoxaluria Type 2", "3-Hydroxyacyl-CoA Dehydrogenase Deficiency", "Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency", "Mitochondrial Trifunctional Protein Deficiency", "Sickle Cell Disease", "Beta-Thalassemia", "Holocarboxylase Synthetase Deficiency", "3-Hydroxy-3-Methylglutaric Aciduria", "Primary Hyperoxaluria Type 3", "Hermansky-Pudlak Syndrome 1", "Hermansky-Pudlak Syndrome 4", "Apparent Mineralocorticoid Excess", "HSDB", "CBAS1", "Mucopolysaccharidosis Type 2", "Mucopolysaccharidosis Type 1", "Severe Combined Immunodeficiency, X Linked", "Severe Combined Immunodeficiency Due to IL-7Ralpha Deficiency", "Diabetes Mellitus, Permanent Neonatal", "Isovaleric Acidemia", "Severe Combined Immunodeficiency T-Cell Negative B-Cell Positive Due to Janus Kinase-3 Deficiency (Disorder)", "Jervell and Lange-Nielsen Syndrome 2", "Hyperinsulinemic Hypoglycemia, Familial, 2", "Diabetes Mellitus, Permanent Neonatal, With Neurologic Features", "Jervell and Lange-Nielsen Syndrome 1", "Lysosomal Acid Lipase Deficiency", "CblF", "3-Methylcrotonyl CoA Carboxylase 1 Deficiency", "3-Methylcrotonyl CoA Carboxylase 2 Deficiency", "Waardenburg Syndrome Type 2A", "Methylmalonic Aciduria cblA Type", "Methylmalonic Aciduria cblB Type", "Methylmalonic Aciduria and Homocystinuria Type cblC", "MAHCD", "Methylmalonic Aciduria Due to Methylmalonyl-CoA Mutase Deficiency", "Congenital Disorder of Glycosylation Type 1B", "Mthfr Deficiency", "Methylcobalamin Deficiency Type Cbl G (Disorder)", "Methylcobalamin Deficiency Type cblE", "Usher Syndrome, Type 1B", "N-acetylglutamate Synthase Deficiency", "Ornithine Transcarbamylase Deficiency", "Phenylketonurias", "Waardenburg Syndrome Type 1", "Congenital Hypothyroidism", "Propionic Acidemia", "Usher Syndrome, Type 1F", "Pancreatic Agenesis 1", "Hereditary Hypophosphatemic Rickets", "Glycogen Storage Disease IXB", "Glycogen Storage Disease IXC", "MOWS", "Epilepsy, Early-Onset, Vitamin B6-Dependent", "Pyridoxal Phosphate-Responsive Seizures", "Pituitary Hormone Deficiency, Combined, 1", "Ptsd", "Dihydropteridine Reductase Deficiency", "Severe Combined Immunodeficiency Due to RAG1 Deficiency", "Severe Combined Immunodeficiency Due to RAG2 Deficiency", "Retinoblastoma", "Multiple Endocrine Neoplasia Type 2B", "Pseudohypoaldosteronism, Type I", "Liddle Syndrome", "Biotin-Responsive Basal Ganglia Disease", "SCD", "DIAR1", "GSD1C", "Acrodermatitis Enteropathica", "Thyroid Dyshormonogenesis 1", "Riboflavin Transporter Deficiency", "Waardenburg Syndrome, Type 2E", "SRD", "Congenital Lipoid Adrenal Hyperplasia Due to STAR Deficiency", "Barth Syndrome", "Adrenocorticotropic Hormone Deficiency", "Transcobalamin II Deficiency", "Thyroid Dyshormonogenesis 3", "Segawa Syndrome, Autosomal Recessive", "Autosomal Recessive Nonsyndromic Hearing Loss", "Thyroid Dyshormonogenesis 2A", "Congenital Isolated Thyroid Stimulating Hormone Deficiency", "Hypothyroidism Due to TSH Receptor Mutations", "Usher Syndrome Type 1C", "Usher Syndrome Type 1G (Diagnosis)", "Von Willebrand Disease, Type 3", "Combined Immunodeficiency Due to ZAP70 Deficiency", "Adenine Phosphoribosyltransferase Deficiency", "Metachromatic Leukodystrophy", "Canavan Disease", "Menkes Disease", "Carbonic Anhydrase VA Deficiency", "Developmental and Epileptic Encephalopathy 2", "17 Alpha-Hydroxylase Deficiency", "Smith-Lemli-Opitz Syndrome", "Krabbe Disease", "Glutathione Synthetase Deficiency", "Mucopolysaccharidosis Type 7", "Rett Syndrome", "Molybdenum Cofactor Deficiency, Type A", "Niemann-Pick Disease, Type C1", "Niemann-Pick Disease Type C2", "Ornithine Aminotransferase Deficiency", "3-Phosphoglycerate Dehydrogenase Deficiency", "Leber Congenital Amaurosis 2", "Dravet Syndrome", "Mucopolysaccharidosis Type 3 A", "Ornithine Translocase Deficiency", "Carnitine-acylcarnitine Translocase Deficiency", "Glucose Transporter Type 1 Deficiency Syndrome", "Creatine Transporter Deficiency", "Niemann-Pick Disease Type A", "Pitt Hopkins Syndrome", "Tuberous Sclerosis 1", "Tuberous Sclerosis 2", "Ataxia With Isolated Vitamin E Deficiency", "Angelman Syndrome", "Prader-Willi Syndrome", "Homocystinuria", "Permanent Neonatal Diabetes Mellitus", "Transient Neonatal Diabetes Mellitus", "Factor VII Deficiency", "Glycogen Storage Disease Type IXA1", "Glycogen Storage Disease, Type IXA2", "Glycogen Storage Disease IC", "Glycogen Storage Disease Type IB", "Central Hypoventilation Syndrome With or Without Hirschsprung Disease" ], "interventions": [ { "name": "Confirmatory Testing", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "RTI International", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Day", "maximum_age": "31 Days", "sex": "ALL", "summary": "1 Day to 31 Days" }, "enrollment_count": 30000, "start_date": "2018-10-15", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-29T21:13:33.311Z", "location_count": 1, "location_summary": "Research Triangle Park, North Carolina", "locations": [ { "city": "Research Triangle Park", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03655223" }, { "nct_id": "NCT06989359", "title": "Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "IgAN", "C3G", "Complement-mediated Kidney Disease", "IgA Nephropathy (IgAN)", "IC-MPGN" ], "interventions": [ { "name": "ADX-038 Dose Level 2", "type": "DRUG" }, { "name": "ADX-038 Dose Level 1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ADARx Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2025-08-28", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-29T21:13:33.311Z", "location_count": 11, "location_summary": "Doral, Florida • Miami, Florida • Pembroke Pines, Florida + 8 more", "locations": [ { "city": "Doral", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06989359" }, { "nct_id": "NCT06921603", "title": "POCUS-Guided Diuresis for Decompensated Heart Failure", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Heart Decompensation, Acute", "Acute Kidney Injuries" ], "interventions": [ { "name": "Furosemide (Standard Diuretic) Treatment", "type": "OTHER" }, { "name": "POCUS-Assessed Diuretic Management", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 588, "start_date": "2025-06-29", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-10-29T21:13:33.311Z", "location_count": 5, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06921603" } ] }